Clinical Trial Update: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 crossover trial evaluating sebetralstat (KVD900) for on-demand treatment of hereditary angioedema attacks in adolescents and adults has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Sebetralstat (KVD900) (sebetralstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2024-07-19